Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)

The three part, double‐blind, randomized, controlled reSURFACE 1 trial and extension study (NCT01722331) evaluated efficacy and safety of tildrakizumab in adults with moderate to severe plaque psoriasis. Patients with ≥50% improvement from baseline in Psoriasis Area and Severity Index (PASI 50) foll...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Dermatol
Prif Awduron: Imafuku, Shinichi, Nakagawa, Hidemi, Igarashi, Atsuyuki, Morita, Akimichi, Okubo, Yukari, Sano, Shigetoshi, Tada, Yayoi, Nemoto, Osamu, Rozzo, Stephen J., Kawamura, Masaki, Ohtsuki, Mamitaro
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2021
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8248015/
https://ncbi.nlm.nih.gov/pubmed/33523513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.15763
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg